IPO - Jyong Biotech Ltd.

Form Type: 8-A12B

Filing Date: 2025-06-12

Corporate Action: Ipo

Type: New

Accession Number: 000121390025053888

Filing Summary: Jyong Biotech Ltd. is registering certain classes of securities, specifically ordinary shares with a par value of US$0.00001 per share, with the SEC. The shares will be listed on The Nasdaq Stock Market LLC. This registration form pertains to Section 12(b) of the Securities Exchange Act of 1934. The registration statement file number is 333-277725, originally filed on March 7, 2024. No exhibits are required to be filed as no other securities are registered. The document is signed by CEO Fu-Feng Kuo on June 12, 2025.

Form Type: POS AM

Filing Date: 2025-06-06

Corporate Action: Ipo

Type: New

Accession Number: 000121390025052132

Filing Summary: Jyong Biotech Ltd. is submitting a Post-Effective Amendment No. 2 to its Form F-1 Registration Statement, which was initially declared effective by the SEC on March 31, 2025. The prospectus pertains to an initial public offering (IPO) of 2,666,667 ordinary shares with a proposed pricing range of USD 7.50 to USD 8.50 per share. The company emphasizes its mission to develop innovative healthcare solutions for urinary system diseases. The document outlines the company's structure, including its operations through various subsidiaries across Taiwan, Singapore, Hong Kong, and the PRC, and details on business strategies and risk factors tied to regulatory issues in China. It highlights ongoing studies for its primary drug candidates MCS-2 and PCP, underscoring challenges faced with the U.S. FDA in prior clinical trials and the withdrawal of a new drug application (NDA) due to insufficient efficacy data. As of the filing date, the company remains an emerging growth entity and intends to utilize proceeds from the IPO for general corporate purposes, including potential developmental costs and operational investments.

Form Type: POS AM

Filing Date: 2025-04-23

Corporate Action: Ipo

Type: New

Accession Number: 000121390025034511

Filing Summary: Jyong Biotech Ltd. has filed a post-effective amendment to its Form F-1 registration statement with the SEC on April 23, 2025, to include audited financial statements for the fiscal year ending December 31, 2024, and updated information. The registration statement was originally effective on March 31, 2025, and the company is launching an initial public offering (IPO) of 2,666,667 ordinary shares, priced between $7.50 and $8.50 each. This amendment does not register additional securities, and fees were previously paid for the original filing. The company anticipates the IPO will be conducted on NASDAQ under the symbol 'MENS', though approval for listing is not yet guaranteed. They are classified as an emerging growth company and are pursuing drug development, particularly focusing on treatments for urinary system diseases.

Form Type: F-1/A

Filing Date: 2025-03-11

Corporate Action: Ipo

Type: New

Accession Number: 000121390025022817

Filing Summary: This document serves as an amendment to the registration statement for Jyong Biotech Ltd.'s initial public offering (IPO) of 2,666,667 ordinary shares. The anticipated pricing for these shares is between $7.50 and $8.50, aiming for total proceeds of approximately $20 million. The company intends to list its shares on Nasdaq under the ticker symbol 'MENS.' This offering allows for an emerging growth company to recruit capital for their operations primarily focusing on innovative drugs for urinary system diseases. The prospectus details the company's structure as a Cayman Islands exempted holding company with operations in multiple countries. The plan includes utilizing funds for the development of their lead product candidate, MCS-2, currently undergoing clinical trials. Notably, the document highlights regulatory uncertainties related to foreign investments and operations in China, which could potentially impact the company’s business strategy and funding availability. The filing clarifies that prior to this offering, there has been no public market for its shares. As part of the registration process, the company assures compliance with relevant regulations and outlines risk factors associated with its business model and market dynamics.

Form Type: F-1/A

Filing Date: 2025-02-06

Corporate Action: Ipo

Type: New

Accession Number: 000121390025010915

Filing Summary: Jyong Biotech Ltd. is conducting its initial public offering (IPO) to offer 2,352,941 ordinary shares at an anticipated price range between $7.50 and $8.50 per share. The company aims to list its shares on the Nasdaq Global Market under the symbol 'MENS'. As of the date of the document, there is no public market for these shares and the application for listing is pending Nasdaq's approval. The prospectus outlines the company's operations, recent developments in drug candidates, including MCS-2 and PCP, focusing on the treatment of urinary system diseases. It emphasizes the company’s status as an emerging growth company and a foreign private issuer, which allows it to follow certain reduced reporting requirements. The document also discusses potential risks related to regulatory scrutiny and the impact of Chinese regulations on its U.S. market access, alongside details about its recent NDA engagements with the U.S. FDA regarding their drug candidates. The summary emphasizes Jyong Biotech’s commitment to innovative drug development and highlights its funding strategy relying heavily on intercompany loans and equity contributions.